Yacht Club de Monaco
'Les Voiles de l'Espoir' arrives in Monaco on the 19th of June
May 29, 2024 04:54 ET | Yacht Club de Monaco
TURIN, Italy, May 29, 2024 (GLOBE NEWSWIRE) -- Supporting children aged 8 to 14 from all backgrounds (France, Morocco, Israel, Luxembourg, Belgium, Switzerland, and other countries) in remission...
Corporate structure reorganization
Burning Rock Reports First Quarter 2024 Financial Results
May 29, 2024 01:34 ET | Burning Rock Biotech Limited
Burning Rock Reports First Quarter 2024 Financial Results
cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics to Participate in Upcoming Investor Conferences
May 28, 2024 08:05 ET | Cargo Therapeutics, Inc.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
May 28, 2024 08:00 ET | Cargo Therapeutics, Inc.
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
G1_Logo_2022_Reg.png
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
May 28, 2024 06:30 ET | G1 Therapeutics
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 ADC
logo_urteste.png
Urteste has successfully developed a prototype urine-based diagnostic test for detecting brain tumours
May 28, 2024 06:24 ET | Urteste S.A.
28 MAY 2024        PRESS RELEASE Urteste has successfully developed a prototype urine-based diagnostic test for detecting brain tumours Gdańsk, Poland – 28 MAY 2024, Urteste S.A. (Warsaw Stock...
cgoncology_cover.jpg
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
May 24, 2024 08:00 ET | CG Oncology Inc.
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
LOGO-01.png
Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024
May 23, 2024 02:00 ET | Burning Rock Biotech Limited
Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024
cmi_logo.png
[Latest] Global Non-Small-Cell Lung Cancer Drug Market Size/Share Worth USD 68,888.6 Million by 2033 at a 8.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 21, 2024 03:30 ET | Custom Market Insights
Austin, TX, USA, May 21, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Non-Small-Cell Lung Cancer Drug Market Size, Trends and Insights By Cancer Type...
cmi_logo.png
[Latest] Global Colorectal Cancer Market Size/Share Worth USD 30,095.9 Million by 2033 at a 3.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 20, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, May 20, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Colorectal Cancer Market Size, Trends and Insights By Type of Treatment (Surgery,...